News and Media
Our latest articles and press releases
The Center for Cancer and Blood Disorders moves forward with Phase II of its Strategic Alliance with VieCure. Commences installation of VCurePrecision™ A.I. Oncology
April 20, 2020
The Center for Cancer and Blood Disorders moves forward with phase II of its strategic alliance with VieCure and commences installation of the VCurePrecision™
ViewRay and VieCure announce Strategic Collaboration to Accelerate Adoption of Personalized
April 1, 2020
Collaboration offers clinicians a personalized oncology solution that combines cutting-edge MRI-guided radiation therapy with a leading A.I.-driven EMR integration platform
Sema4 and VieCure announce Strategic Collaboration to Accelerate Precision
March 2, 2020
The combination of health intelligence and oncology EMR expertise will give oncologists more real-time patient insights and increased awareness
of clinical trials.
VieCure chooses Microsoft Azure for their cloud-based A.I. platform and smart
EMR in oncology
October 16, 2019
VieCure, a rapidly growing cancer care company with an A.I. enabled clinical decision support platform in oncology, announced that it has chosen Microsoft Azure to host its platform
The Center for Cancer and Blood Disorders aligns with VieCure to provide A.I. driven precision oncology to cancer patients in Texas
September 5, 2019
CCBD and VieCure announced an important strategic collaboration agreement to create a leading clinical reference site for cancer treatment excellence.
VieCure is excited to announce its Clinical Advisory Council!
August 19, 2019
The CAC comprises global leaders from top cancer programs who review clinical evidence and literature to develop algorithms and codified clinical
rules for VCurePrecision™.
VieCure A.I. platform and embedded 'Smart' EMR selected by The Cancer Centres of the Bahamas and Eastern Caribbean
January 10, 2019
VieCure announced today its VCurePrecision™ platform has been selected by the leadership at The Cancer Centre Bahamas (TCCB, Nassau) and The Cancer Centre Eastern Caribbean (TCCEC, Antigua) as the preferred solution to support their clinical operations. The Centre in the Bahamas has treated thousands of patients dating back to 2004 and the relatively new Centre in Antigua for The Organization of Eastern Caribbean States (OECS) has been
operational since 2015.
VieCure collaborates with Adaptive Biotechnologies
January 10, 2019
VieCure and Adaptive Biotechnologies (Adaptive) announced a collaboration in which VieCure will build, test and validate the required code and related algorithms as well as identify, review and codify relevant clinical references into VieCure’s Artificial Intelligence (AI) platform. The resulting logic will be deployed via the platform’s cloud-based hosting environment to facilitate rapid education, awareness and understanding of the appropriate timepoints for use of Adaptive’s clonoSEQ Assay in the Multiple Myeloma (MM) and Acute Lymphoblastic Leukemia (ALL) patient populations. VieCure will also work with Adaptive to design and build appropriate analytics to measure incorporation of the clonoSEQ Assay.
Baptist Health to improve cancer care with VCurePrecision™
March 5, 2018
MONTGOMERY, AL (March 5, 2018) (VieCure and related products are the property of Viviphi Ltd) VieCure and Baptist Health announced today that the VCurePrecision platform will be deployed across the central Alabama cancer network, offering personalized cancer treatment to an estimated 4,000 patients annually throughout the region.
Get in touch with our marketing and media team
VieCure and Avera Health confirm clinical validation and system-wide implementation
of A.I. platform
June 2, 2017
VieCure (Greenwood Village, CO) and Avera Health (Sioux Falls, SD) announce that the VCurePrecision™ platform will be fully implemented across the multi-state cancer system. The platform was developed through a clinical collaboration between
the two organizations.
VieCure and OncBioMune d/b/a Theralink® Technologies Announces Strategic Agreement to Improve Outcomes for Breast Cancer Patients Being Treated in Community Oncology Settings
July 8, 2020
OncBioMune d/b/a Theralink® Technologies (OTC: OBMP), a molecular profiling company specializing in biomarker assay services that target multiple areas of oncology, announced today the signing a mutli-year strategic agreement with VieCure™ to enhance personalized cancer treatment in
community oncology settings.